ArticleHIV medicine2026
Menopause and comorbidity assessment in cisgender women living with HIV in Victoria: A clinic record review of women seen at three tertiary centres in Melbourne, Australia.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundData on women ageing with HIV in Australia are limited, particularly regarding those in midlife and experiencing menopause. The aim of this study is to describe the demographic characteristics of cisgender women living with HIV who attend the Alfred Hospital, Monash Medical Centre and Melbourne Sexual Health Centre for primary HIV care. In particular, we sought to identify whether documentation of menopausal status, menopausal symptoms, use of menopausal hormone therapy (MHT) and comorbidity screening had occurred in these women.
methodsCisgender women currently in care (defined as attending the clinic between 1/7/2022 and 1/7/2024) were identified and a medical record review was conducted to identify demographic information, menopausal status, menopausal symptoms, use of MHT and documentation of related comorbidity screening results (cervical screening test [CST], mammogram, fracture risk (FRAX), bone density (DEXA), cardiovascular disease [CVD] risk).
resultsA total of 462 women were identified across the three sites. Median age was 47 years (range 20-85, interquartile range [IQR] 39-56) and the majority (342, 70%) were born overseas. Of these, 148 (32%) were pre-menopausal, 47 (10%) perimenopausal and 145 (31%) post-menopausal. Menopausal status was unable to be determined from clinical records for 122 (26%). Menopausal symptoms were documented for 70 women (age range 38-85, IQR 48-57). Cervical screening was completed in the last 3 years for 293 women (66%) aged 25-74 years, 58 (30%) over 50 years had documentation of a mammogram in the last 2 years, 105 (39%) over 45 years had CVD risk calculated and 17 (29%) over 50 years had FRAX calculated.
conclusionApproximately half the women in this study were aged 40-56 years, yet menopausal status was unable to be determined for over a quarter of the cohort. Documentation of menstrual or menopausal symptoms was poor and significant gaps were identified in comorbidity screening. Further research is needed to understand the impact of menopause on women living with HIV in Australia. Clinical guidelines need updating to include gender-specific health needs of women living with HIV and to consider the impact of menopause on comorbidity management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.